Quantcast
Last updated on April 20, 2014 at 13:20 EDT

CardioDx to Present at Cowen and Company 33rd Annual Healthcare Conference

February 25, 2013

PALO ALTO, Calif., Feb. 25, 2013 /PRNewswire/ — CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the Cowen and Company 33(rd) Annual Healthcare Conference on Monday, March 4, 2013 at 10:00 a.m. ET at the Boston Marriott Copley Place in Boston. Andrew Guggenhime, the company’s Chief Financial Officer, will provide an overview of CardioDx and Corus® CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD).

(Logo: http://photos.prnewswire.com/prnh/20130219/MM60898 )

CardioDx recently announced the publication of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) study in Circulation: Cardiovascular Genetics, a peer-reviewed journal of the American Heart Association. Results of the prospective, multi-center U.S. study showed that Corus CAD outperformed traditional stress testing with myocardial perfusion imaging (MPI), demonstrating high accuracy with both a higher sensitivity (89 percent vs. 27 percent) and higher negative predictive value (96 percent vs. 88 percent) than MPI for assessing obstructive CAD.

With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient’s symptoms are due to obstructive CAD, enabling many patients to avoid unnecessary noninvasive and invasive cardiac procedures and exposure to imaging-related radiation risks or imaging agent intolerance. Corus CAD is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has been used commercially by clinicians in more than 35,000 patients and is a covered benefit for more than 40 million Medicare enrollees in the U.S.

Corus CAD has been recognized by The Wall Street Journal‘s Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME‘s Top Ten Medical Breakthroughs. CardioDx was recently honored as one of FierceMedicalDevices‘ “Fierce 15″ most promising privately-held medical device and diagnostic companies.

About CardioDx

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.

SOURCE CardioDx, Inc.


Source: PR Newswire